Cordis Reveals 12-Month Outcomes of SELUTION SLR™ Trials at TCT 2025

Cordis to Present Pivotal 12-Month Results at TCT 2025

Cordis, recognized as a leader in interventional cardiovascular technologies, is set to unveil critical 12-month results from two significant randomized clinical trials of its SELUTION SLR™ Drug-Eluting Balloon (DEB) technology at the upcoming Transcatheter Cardiovascular Therapeutics® (TCT®) conference. This event, scheduled for October 26, 2025, will take place in San Francisco during the Late-Breaking Clinical Trials session.

The focus of these trials is on the SELUTION4ISR and SELUTION DeNovo, which are poised to offer valuable insights into the effectiveness of Cordis’ DEB technology. The SELUTION DeNovo trial, led by Professor Christian M. Spaulding from the Hôpital Européen Georges-Pompidou in Paris, France, involves 3,323 patients and compares the SELUTION SLR™ DEB to the traditional Drug Eluting Stent (DES) for treating de novo coronary artery disease. Preliminary data suggests promising outcomes for the SELUTION SLR™ strategy in improving patient health compared to DES.

In parallel, Dr. Donald Cutlip from the Beth Israel Deaconess Medical Center and Baim Institute for Clinical Research in Boston, USA, will present findings from the SELUTION4ISR trial. This study involves 418 participants and evaluates the SELUTION SLR™ DEB against standard care, including DES and Balloon Angioplasty for the treatment of In-Stent Restenosis (ISR).

George Adams, MD, Chief Medical Officer at Cordis, expressed enthusiasm about sharing these pivotal findings with the medical community. “We are thrilled to present our 12-month data, which not only highlight the safety and clinical value of the SELUTION SLR™ DEB compared to existing therapies but also assist cardiologists in integrating drug-eluting balloons into their treatment algorithms effectively,” he stated.

Innovation and Discussion at TCT 2025

Beyond the data presentation, Cordis has organized two symposia at TCT 2025 that aim to delve deeper into the trial results. Attendees can participate in "Meet the SELUTION Trialists: A Fireside Chat" and "A New Era of Drug Elution: An Unfiltered Discussion on the 12-Month Results from SELUTION4ISR and SELUTION DeNovo." These discussions will provide attendees with an opportunity to engage directly with the principal investigators behind these studies, facilitating a better understanding of the implications of the findings.

For those interested in the ongoing evolution of cardiovascular therapies, these presentations and discussions underscore Cordis' commitment to innovating patient care and improving outcomes in cardiovascular health. The SELUTION SLR™ DEB technology, which is commercially available in over 65 countries and under investigation in the U.S., utilizes the Sustained Limus Release (SLR) technology to ensure controlled drug release over a duration of 90 days, targeting the full restenosis cascade.

Growth and Opportunities at Cordis

As Cordis continues to push forward with innovative developments in coronary and peripheral vascular markets, the company is also expanding its U.S. Sales Team. Aspiring candidates seeking opportunities in sales or related fields are encouraged to visit the Cordis Careers page to stay updated.

With a commitment to excellence showcased through over 60 years of innovation in the cardiovascular arena, Cordis remains at the forefront of advancements that aim to redefine cardiovascular treatment protocols. Their efforts in clinical research, product development, and interactive discussions aim to enhance education and drive significant improvements in patient care.

For further information on Cordis’ activities at TCT 2025, prospective attendees can visit the Cordis TCT page.